PMID- 37106239
OWN - NLM
STAT- MEDLINE
DCOM- 20230829
LR  - 20230829
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 25
IP  - 10
DP  - 2023 Oct
TI  - Local treatment in oligometastasis from breast cancer: an overview.
PG  - 2861-2867
LID - 10.1007/s12094-023-03170-0 [doi]
AB  - Oligometastasic breast cancer (OMBC) consists of breast cancer patient with a 
      limited number of systemic metastases (</= 5), all of them candidates for local 
      ablative treatment with the intention of achieving long-term control of the 
      metastasis and, eventually, an increase in survival The first consensus for the 
      management of patients with oligometastatic breast cancer (OMBC) was published in 
      2007, establishing that a more aggressive multidisciplinary strategy is 
      recommended in order to increase the survival while maintaining a good quality of 
      life. The current scientific evidence is based on observational studies, mainly 
      retrospective, systematic reviews and meta-analyses, and only a randomized 
      nonexclusive study of oligometastatic (OM) published. All trials with 
      Stereotactic Body Radiation Therapy (SBRT) in OM cancer have shown excellent 
      tolerance and good local control, although first trials on Lung SBRT did not 
      prove so excellent tolerance and had some deaths due to bronchus irradiation and 
      secondary hemoptysis. There are multiple ongoing studies researching the benefit 
      of SBRT in oligometastatic breast cancer. Despite the lack of impact on survival 
      seen in the NRG BR-002 Trial, SBRT probably allows the delay of the systemic 
      treatment until progression, and so, improves the quality of life of patients. We 
      have to wait for the results of the ongoing and future studies for clarification 
      of the role of local treatment in OMBC.
CI  - (c) 2023. The Author(s), under exclusive licence to Federacion de Sociedades 
      Espanolas de Oncologia (FESEO).
FAU - Burgaleta, Ana Manterola
AU  - Burgaleta AM
AD  - Multidisciplinary Breast Cancer Unit, Radiation Oncology Service, University 
      Hospital of Navarre, Pamplona, Spain.
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain.
FAU - Burguete, Andrea Barco
AU  - Burguete AB
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain.
FAU - Gutierrez, Lombardo Rosas
AU  - Gutierrez LR
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain.
FAU - Nuin, Erkuden Burillo
AU  - Nuin EB
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain.
FAU - Felipe, Gemma Asin
AU  - Felipe GA
AD  - Multidisciplinary Breast Cancer Unit, Radiation Oncology Service, University 
      Hospital of Navarre, Pamplona, Spain.
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain.
FAU - de la Vega, Fernando Arias
AU  - de la Vega FA
AUID- ORCID: 0000-0003-1288-9356
AD  - Service of Radiotherapy Oncology, University Hospital of Navarre, Pamplona, 
      Spain. fariasde@cfnavarra.es.
AD  - "Clinical Research Group in Radiation Oncology", Health Research Institute of 
      Navarra (IdiSNA), Pamplona, Spain. fariasde@cfnavarra.es.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230427
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/therapy
MH  - Retrospective Studies
MH  - Quality of Life
MH  - *Radiosurgery/methods
OTO - NOTNLM
OT  - Breast cancer
OT  - Oligometastasis
OT  - SBRT
EDAT- 2023/04/28 00:42
MHDA- 2023/08/29 12:42
CRDT- 2023/04/27 23:29
PHST- 2023/01/17 00:00 [received]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2023/08/29 12:42 [medline]
PHST- 2023/04/28 00:42 [pubmed]
PHST- 2023/04/27 23:29 [entrez]
AID - 10.1007/s12094-023-03170-0 [pii]
AID - 10.1007/s12094-023-03170-0 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2023 Oct;25(10):2861-2867. doi: 10.1007/s12094-023-03170-0. 
      Epub 2023 Apr 27.